NEW YORK – Immunovant, Inc. (NASDAQ:), a clinical-stage immunology company, has been awarded a U.S. patent for a second-generation antibody, IMVT-1402, that targets autoimmune diseases. The United States Patent and Trademark Office has issued Patent No. 11,926,669, which claims include the composition of a substance for binding the sequence of IMVT-1402 to a neonatal fragment crystallizing receptor (FcRn), its method of use in the treatment of autoimmune diseases and methods of production.
The patent expires on June 23, 2043, excluding any potential patent term extensions.
IMVT-1402, developed through HanAll Biopharma’s antibody discovery efforts, showed promising results in a Phase 1 clinical trial in healthy adults. Initial results from the study showed a significant reduction in immunoglobulin G (IgG) levels, comparable to batoclimab, another antibody of the same class, but without noticeable changes in serum albumin and LDL cholesterol levels. Immunovant suggests that weekly administration of IMVT-1402 may maintain consistent reductions in IgG levels, which may be critical for sustained efficacy in patients.
The company’s primary focus is on developing treatments for autoimmune diseases to improve the quality of life of affected individuals. However, it is important to note that early results from clinical trials may not always be indicative of definitive results, and further studies are needed to confirm the safety and effectiveness of IMVT-1402.
Immunovant’s progress in developing IMVT-1402 and acquisition of the patent represent steps forward in its efforts to address the complex needs of people with autoimmune diseases. However, the company acknowledges the inherent uncertainties and risks associated with drug development, including the need for additional capital and the challenges of navigating the regulatory environment.
This news is based on a press statement from Immunovant, Inc. Investors and stakeholders are reminded that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.
This article was created with the help of AI and reviewed by an editor. For more information please see our Terms and Conditions.